Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention

Infectious Disease Clinics of North America

Volumn 25, Issue 1, 2011, Pages 201-225

  Alangaden, George J ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspergillus; Candida; Fungal infection; Nosocomial

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ATOVAQUONE; CHLORHEXIDINE; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; DAPSONE; DEFEROXAMINE; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; PENTAMIDINE; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; PYRROLE DERIVATIVE; STEROID; VANCOMYCIN; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CANDIDIASIS; CATHETER INFECTION; DRUG MEGADOSE; EPIDEMIC; FUSARIUM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MALASSEZIA; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PICHIA GUILLIERMONDII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PREVENTIVE HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK FACTOR; ZYGOMYCETES; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CROSS INFECTION; HUMANS; MYCOSES; PREVALENCE; RISK FACTORS;

EID: 79551706208     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.11.003     Document Type: Review

References (184)

1. Fridkin S.K. The changing face of fungal infections in health care settings. Clin Infect Dis 2005, 41(10):1455-1460.
2. Segal B.H., Kwon-Chung J., Walsh T.J., et al. Immunotherapy for fungal infections. Clin Infect Dis 2006, 42(4):507-515.
3. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29(11):996-1011.
4. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
5. Vonberg R.P., Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect 2006, 63(3):246-254.
6. Bouza E., Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008, 32(Suppl 2):S87-S91.
7. Tortorano A.M., Caspani L., Rigoni A.L., et al. Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004, 57(1):8-13.
8. Trick W.E., Fridkin S.K., Edwards J.R., et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35(5):627-630.
9. Pappas P.G., Rex J.H., Lee J., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37(5):634-643.
10. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20(1):133-163.
11. Almirante B., Rodriguez D., Park B.J., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43(4):1829-1835.
12. Hajjeh R.A., Sofair A.N., Harrison L.H., et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42(4):1519-1527.
13. Marchetti O., Bille J., Fluckiger U., et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38(3):311-320.
14. Richet H.M., McNeil M.M., Edwards M.C., et al. Cluster of Malassezia furfur pulmonary infections in infants in a neonatal intensive-care unit. J Clin Microbiol 1989, 27(6):1197-1200.
15. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006, 25(7):419-425.
16. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41(9):1232-1239.
17. Morgan J., Meltzer M.I., Plikaytis B.D., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26(6):540-547.
18. Smith P.B., Morgan J., Benjamin J.D., et al. Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J 2007, 26(3):197-200.
19. Wilson L.S., Reyes C.M., Stolpman M., et al. The direct cost and incidence of systemic fungal infections. Value Health 2002, 5(1):26-34.
20. Dasbach E.J., Davies G.M., Teutsch S.M. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis 2000, 31(6):1524-1528.
21. Neofytos D., Horn D., Anaissie E., et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009, 48(3):265-273.
22. Upton A., Kirby K.A., Carpenter P., et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007, 44(4):531-540.
23. Boyce J.M., Pittet D. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002, 51(RR-16):1-45. [quiz: CE41-4].
24. O'Grady N.P., Alexander M., Dellinger E.P., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002, 51(RR-10):1-29.
25. Marschall J., Mermel L.A., Classen D., et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol 2008, 29(Suppl 1):S22-S30. [Erratum in: Infect Control Hosp Epidemiol 2009;30:815].
26. Sehulster L., Chinn R.Y. Guidelines for environmental infection control in health-care facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003, 52(RR-10):1-42.
27. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15(10):1143-1238.
28. Nucci M., Anaissie E. Revisiting the source of candidemia: skin or gut?. Clin Infect Dis 2001, 33(12):1959-1967.
29. Blumberg H.M., Jarvis W.R., Soucie J.M., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33(2):177-186.
30. Vazquez J.A., Sanchez V., Dmuchowski C., et al. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993, 168(1):195-201.
31. Vazquez J.A., Dembry L.M., Sanchez V., et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol 1998, 36(2):421-426.
32. Berger C., Frei R., Gratwohl A., et al. Bottled lemon juice - a cryptic source of invasive Candida infections in the immunocompromised host. J Infect Dis 1988, 158(3):654-655.
33. Kuhn D.M., Ghannoum M.A. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004, 5(2):186-197.
34. Kuhn D.M., Chandra J., Mukherjee P.K., et al. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002, 70(2):878-888.
35. Asmundsdottir L.R., Erlendsdottir H., Haraldsson G., et al. Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008, 47(2):e17-e24.
36. Kao A.S., Brandt M.E., Pruitt W.R., et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999, 29(5):1164-1170.
37. Leon C., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (" Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34(3):730-737.
38. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26(4):271-276.
39. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007, 45(6):1735-1745.
40. Abi-Said D., Anaissie E., Uzun O., et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24(6):1122-1128.
41. Horn D.L., Neofytos D., Anaissie E.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48(12):1695-1703.
42. Hachem R., Hanna H., Kontoyiannis D., et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008, 112(11):2493-2499.
43. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999, 29(2):253-258.
44. Parry M.F., Grant B., Yukna M., et al. Candida osteomyelitis and diskitis after spinal surgery: an outbreak that implicates artificial nail use. Clin Infect Dis 2001, 32(3):352-357.
45. Pfaller M.A. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996, 22(Suppl 2):S89-S94.
46. Robert F., Lebreton F., Bougnoux M.E., et al. Use of random amplified polymorphic DNA as a typing method for Candida albicans in epidemiological surveillance of a burn unit. J Clin Microbiol 1995, 33(9):2366-2371.
47. Gupta N., Haque A., Lattif A.A., et al. Epidemiology and molecular typing of Candida isolates from burn patients. Mycopathologia 2004, 158(4):397-405.
48. Fanello S., Bouchara J.P., Jousset N., et al. Nosocomial Candida albicans acquisition in a geriatric unit: epidemiology and evidence for person-to-person transmission. J Hosp Infect 2001, 47(1):46-52.
49. Malani A., Hmoud J., Chiu L., et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005, 41(7):975-981.
50. Marr K.A. The changing spectrum of candidemia in oncology patients: therapeutic implications. Curr Opin Infect Dis 2000, 13(6):615-620.
51. Lin M.Y., Carmeli Y., Zumsteg J., et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 2005, 49(11):4555-4560.
52. Levy I., Rubin L.G., Vasishtha S., et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998, 26(5):1086-1088.
53. Lupetti A., Tavanti A., Davini P., et al. Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol 2002, 40(7):2363-2369.
54. Saiman L., Ludington E., Pfaller M., et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000, 19(4):319-324.
55. Almirante B., Rodriguez D., Cuenca-Estrella M., et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006, 44(5):1681-1685.
56. Saiman L., Ludington E., Dawson J.D., et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001, 20(12):1119-1124.
57. Bonassoli L.A., Bertoli M., Svidzinski T.I. High frequency of Candida parapsilosis on the hands of healthy hosts. J Hosp Infect 2005, 59(2):159-162.
58. van Asbeck E.C., Huang Y.C., Markham A.N., et al. Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies. Mycopathologia 2007, 164(6):287-293.
59. Kuhn D.M., Mikherjee P.K., Clark T.A., et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004, 10(6):1074-1081.
60. Clark T.A., Slavinski S.A., Morgan J., et al. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol 2004, 42(10):4468-4472.
61. Levin A.S., Costa S.F., Mussi N.S., et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998, 30(4):243-249.
62. Trofa D., Gacser A., Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21(4):606-625.
63. Sipsas N.V., Lewis R.E., Tarrand J., et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009, 115(20):4745-4752.
64. Kontoyiannis D.P., Vaziri I., Hanna H.A., et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001, 33(10):1676-1681.
65. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol 2008, 46(2):515-521.
66. Abbas J., Bodey G.P., Hanna H.A., et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med 2000, 160(17):2659-2664.
67. Hope W., Morton A., Eisen D.P. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002, 50(1):56-65.
68. Playford E.G., Marriott D., Nguyen Q., et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008, 36(7):2034-2039.
69. Masala L., Luzzati R., Maccacaro L., et al. Nosocomial cluster of Candida guillermondii fungemia in surgical patients. Eur J Clin Microbiol Infect Dis 2003, 22(11):686-688.
70. Minces L.R., Ho K.S., Veldkamp P.J., et al. Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature. Scand J Infect Dis 2009, 41(11-12):892-897.
71. Colombo A.L., Melo A.S., Crespo Rosas R.F., et al. Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. Diagn Microbiol Infect Dis 2003, 46(4):253-257.
72. Barber G.R., Brown A.E., Kiehn T.E., et al. Catheter-related Malassezia furfur fungemia in immunocompromised patients. Am J Med 1993, 95(4):365-370.
73. Chang H.J., Miller H.L., Watkins N., et al. An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. N Engl J Med 1998, 338(11):706-711.
74. Chryssanthou E., Broberger U., Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr 2001, 90(3):323-327.
75. Krcmery V., Mateicka F., Kunova A., et al. Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer 1999, 7(1):39-43.
76. Kontoyiannis D.P., Torres H.A., Chagua M., et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004, 36(8):564-569.
77. Girmenia C., Pagano L., Martino B., et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005, 43(4):1818-1828.
78. Cawley M.J., Braxton G.R., Haith L.R., et al. Trichosporon beigelii infection: experience in a regional burn center. Burns 2000, 26(5):483-486.
79. Wolf D.G., Falk R., Hacham M., et al. Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units. J Clin Microbiol 2001, 39(12):4420-4425.
80. Ruan S.Y., Chien J.Y., Hsueh P.R. Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan. Clin Infect Dis 2009, 49(1):e11-e17.
81. Hajjeh R.A., Warnock D.W. Counterpoint: invasive aspergillosis and the environment - rethinking our approach to prevention. Clin Infect Dis 2001, 33(9):1549-1552.
82. Patterson J.E., Zidouh A., Miniter P., et al. Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. Infect Control Hosp Epidemiol 1997, 18(2):104-108.
83. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect 2009, 15(Suppl 5):55-59.
84. Anaissie E.J., Kuchar R.T., Rex J.H., et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33(11):1871-1878.
85. Alvarez M., Lopez Ponga B., Rayon C., et al. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 1995, 33(12):3290-3295.
86. Guerrero A., Torres P., Duran M.T., et al. Airborne outbreak of nosocomial Scedosporium prolificans infection. Lancet 2001, 357(9264):1267-1268.
87. Fox B.C., Chamberlin L., Kulich P., et al. Heavy contamination of operating room air by Penicillium species: identification of the source and attempts at decontamination. Am J Infect Control 1990, 18(5):300-306.
88. Krishnan S., Manavathu E.K., Chandrasekar P.H. Aspergillus flavus: an emerging non-fumigatus Aspergillus species of significance. Mycoses 2009, 52(3):206-222.
89. Pegues C.F., Daar E.S., Murthy A.R. The epidemiology of invasive pulmonary aspergillosis at a large teaching hospital. Infect Control Hosp Epidemiol 2001, 22(6):370-374.
90. Heinemann S., Symoens F., Gordts B., et al. Environmental investigations and molecular typing of Aspergillus flavus during an outbreak of postoperative infections. J Hosp Infect 2004, 57(2):149-155.
91. Denning D.W., Marinus A., Cohen J., et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998, 37(2):173-180.
92. Lortholary O., Ascioglu S., Moreau P., et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: a European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Intergroupe Francais du Myelome. Clin Infect Dis 2000, 30(1):41-46.
93. Paterson D.L., Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999, 78(2):123-138.
94. Williamson E.C., Millar M.R., Steward C.G., et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999, 104(3):560-568.
95. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100(13):4358-4366.
96. Barnes P.D., Marr K.A. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol 2007, 139(4):519-531.
97. Singh N. Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management. Med Mycol 2005, 43(Suppl 1):S267-S270.
98. Singh N., Avery R.K., Munoz P., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003, 36(1):46-52.
99. Woitas R.P., Rockstroh J.K., Theisen A., et al. Changing role of invasive aspergillosis in AIDS-a case control study. J Infect 1998, 37(2):116-122.
100. Libanore M., Prini E., Mazzetti M., et al. Invasive Aspergillosis in Italian AIDS patients. Infection 2002, 30(6):341-345.
101. Wallace J.M., Lim R., Browdy B.L., et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998, 114(1):131-137.
102. Wallace M.R., Kanak R.J., Newton J.A., et al. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994, 19(1):222.
103. Segal B.H., Romani L.R. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009, 47(Suppl 1):S282-S290.
104. Meersseman W., Lagrou K., Maertens J., et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007, 45(2):205-216.
105. Meersseman W., Van Wijngaerden E. Invasive aspergillosis in the ICU: an emerging disease. Intensive Care Med 2007, 33(10):1679-1681.
106. Vandewoude K.H., Blot S.I., Benoit D., et al. Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence. J Hosp Infect 2004, 56(4):269-276.
107. Cornillet A., Camus C., Nimubona S., et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006, 43(5):577-584.
108. Meersseman W., Vandecasteele S.J., Wilmer A., et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170(6):621-625.
109. Garnacho-Montero J., Amaya-Villar R., Ortiz-Leyba C., et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005, 9(3):R191-R199.
110. Denning D.W. Aspergillosis in " nonimmunocompromised" critically ill patients. Am J Respir Crit Care Med 2004, 170(6):580-581.
111. Anaissie E.J., Costa S.F. Nosocomial aspergillosis is waterborne. Clin Infect Dis 2001, 33(9):1546-1548.
112. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002, 34(6):780-789.
113. Anaissie E.J., Stratton S.L., Dignani M.C., et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003, 101(7):2542-2546.
114. Bryce E.A., Walker M., Scharf S., et al. An outbreak of cutaneous aspergillosis in a tertiary-care hospital. Infect Control Hosp Epidemiol 1996, 17(3):170-172.
115. McCarty J.M., Flam M.S., Pullen G., et al. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. J Pediatr 1986, 108(5 Pt 1):721-724.
116. Leenders A., van Belkum A., Janssen S., et al. Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. J Clin Microbiol 1996, 34(2):345-351.
117. Leenders A.C., van Belkum A., Behrendt M., et al. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol 1999, 37(6):1752-1757.
118. Morris G., Kokki M.H., Anderson K., et al. Sampling of Aspergillus spores in air. J Hosp Infect 2000, 44(2):81-92.
119. Debeaupuis J.P., Sarfati J., Chazalet V., et al. Genetic diversity among clinical and environmental isolates of Aspergillus fumigatus. Infect Immun 1997, 65(8):3080-3085.
120. Kidd S.E., Ling L.M., Meyer W., et al. Molecular epidemiology of invasive aspergillosis: lessons learned from an outbreak investigation in an Australian hematology unit. Infect Control Hosp Epidemiol 2009, 30(12):1223-1226.
121. Balajee S.A., Borman A.M., Brandt M.E., et al. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here?. J Clin Microbiol 2009, 47(4):877-884.
122. Rees J.R., Pinner R.W., Hajjeh R.A., et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998, 27(5):1138-1147.
123. Torres-Narbona M., Guinea J., Martinez-Alarcon J., et al. Impact of zygomycosis on microbiology workload: a survey study in Spain. J Clin Microbiol 2007, 45(6):2051-2053.
124. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005, 41(5):634-653.
125. Rogers T.R. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2007, 61:I35-I39.
126. Christiaens G., Hayette M.P., Jacquemin D., et al. An outbreak of Absidia corymbifera infection associated with bandage contamination in a burns unit. J Hosp Infect 2005, 61(1):88.
127. Garner D., Machin K. Investigation and management of an outbreak of mucormycosis in a paediatric oncology unit. J Hosp Infect 2008, 70(1):53-59.
128. Abzug M.J., Gardner S., Globe M.P., et al. Heliport-associated nosocomial mucormycoses. Infect Control Hosp Epidemiol 1992, 13(6):325-326.
129. Levy V., Rio B., Bazarbachi A., et al. Two cases of epidemic mucormycosis infection in patients with acute lymphoblastic leukemia. Am J Hematol 1996, 52(1):64-65.
130. Mitchell S.J., Gray J., Morgan M.E., et al. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 1996, 348(9025):441-443.
131. Maravi-Poma E., Rodriguez-Tudela J.L., de Jalon J.G., et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med 2004, 30(4):724-728.
132. LeMaile-Williams M., Burwell L.A., Salisbury D., et al. Outbreak of cutaneous Rhizopus arrhizus infection associated with karaya ostomy bags. Clin Infect Dis 2006, 43(9):E83-E88.
133. Cheng V.C.C., Chan J.F.W., Ngan A.H.Y., et al. Outbreak of intestinal infection due to Rhizopus microsporus. J Clin Microbiol 2009, 47(9):2834-2843.
134. Chang D.C., Grant G.B., O'Donnell K., et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006, 296(8):953-963.
135. Saw S.M., Ooi P.L., Tan D.T.H., et al. Risk factors for contact lens-related Fusarium keratitis - a case-control study in Singapore. Arch Ophthalmol 2007, 125(5):611-617.
136. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38(9):1237-1242.
137. Sampathkumar P., Paya C.V. Fusarium infection after solid-organ transplantation. Clin Infect Dis 2001, 32(8):1237-1240.
138. O'Donnell K., Sutton D.A., Rinaldi M.G., et al. Genetic diversity of human pathogenic members of the Fusarium oxysporum complex inferred from multilocus DNA sequence data and amplified fragment length polymorphism analyses: evidence for the recent dispersion of a geographically widespread clonal lineage and nosocomial origin. J Clin Microbiol 2004, 42(11):5109-5120.
139. Ruiz-Diez B., Martin-Diez F., Rodriguez-Tudela J.L., et al. Use of random amplification of polymorphic DNA (RAPD) and PCR-fingerprinting for genotyping a Scedosporium prolificans (inflatum) outbreak in four leukemic patients. Curr Microbiol 1997, 35(3):186-190.
140. Tarkkanen A., Raivio V., Anttila V.J., et al. Fungal endophthalmitis caused by Paecilomyces variotii following cataract surgery: a presumed operating room air-conditioning system contamination. Acta Ophthalmol Scand 2004, 82(2):232-235.
141. Orth B., Frei R., Itin P.H., et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 1996, 125(10):799-806.
142. Proia L.A., Hayden M.K., Kammeyer P.L., et al. Phialemonium: an emerging mold pathogen that caused 4 cases of hemodialysis-associated endovascular infection. Clin Infect Dis 2004, 39(3):373-379.
143. Clark T., Huhn G.D., Conover C., et al. Outbreak of bloodstream infection with the mold Phialemonium among patients receiving dialysis at a hemodialysis unit. Infect Control Hosp Epidemiol 2006, 27(11):1164-1170.
144. Rao C.Y., Pachucki C., Cali S., et al. Contaminated product water as the source of Phialemonium curvatum bloodstream infection among patients undergoing hemodialysis. Infect Control Hosp Epidemiol 2009, 30(9):840-847.
145. Strahilevitz J., Rahav G., Schroers H.J., et al. An outbreak of Phialemonium infective endocarditis linked to intracavernous penile injections for the treatment of impotence. Clin Infect Dis 2005, 40(6):781-786.
146. Kainer M.A., Keshavarz H., Jensen B.J., et al. Saline-filled breast implant contamination with Curvularia species among women who underwent cosmetic breast augmentation. J Infect Dis 2005, 192(1):170-177.
147. Vargas S.L., Ponce C.A., Gigliotti F., et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000, 38(4):1536-1538.
148. Miller R.F., Ambrose H.E., Novelli V., et al. Probable mother-to-infant transmission of Pneumocystis carinii f. sp. hominis infection. J Clin Microbiol 2002, 40(4):1555-1557.
149. Schmoldt S., Bader L., Huber I., et al. Molecular evidence of Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. Int J Med Microbiol 2007, 297:64-65.
150. Mueller N.J., Haeberli L., Joos B., et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients. Am J Transplant 2009, 9:331.
151. Goto N., Yazaki H., Uchida K., et al. Major outbreak of Pneumocystis jiroveci pneumonia in a renal transplant unit. Am J Transplant 2009, 9:640.
152. Hocker B., Wendt C., Nahimana A., et al. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis 2005, 11(2):330-332.
153. de Boer M.G., Bruijnesteijn van Coppenraet L.E., Gaasbeek A., et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source?. Clin Infect Dis 2007, 44(9):1143-1149.
154. Hughes W.T. Transmission of Pneumocystis species among renal transplant recipients. Clin Infect Dis 2007, 44(9):1150-1151.
155. Rabodonirina L., Vanhems P., Couray-Targe S., et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004, 10(10):1766-1773.
156. Gianella S., Haeberli L., Joos B., et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients. Swiss Med Wkly 2009, 139(9-10):5S.
157. Wohl A.R., Simon P., Hu Y.W., et al. The role of person-to-person transmission in an epidemiologic study of Pneumocystis carinii pneumonia. AIDS 2002, 16(13):1821-1825.
158. Manoloff E.S., Francioli P., Taffe P., et al. Risk for Pneumocystis carinii transmission among patients with pneumonia: a molecular epidemiology study. Emerg Infect Dis 2003, 9(1):132-134.
159. Tablan O.C., Anderson L.J., Besser R., et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004, 53(RR-3):1-36.
160. Pronovost P., Needham D., Berenholtz S., et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006, 355(26):2725-2732.
161. Berenholtz S.M., Pronovost P.J., Lipsett P.A., et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med 2004, 32(10):2014-2020.
162. Walsh T.J., Anaissie E.J., Denning D.W., et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008, 46(3):327-360.
163. Hospital epidemiology and infection control 2004, Lippincott Williams and Wilkins, Phildelphia, p. 1549-75. 3rd edition. C. Mayhall (Ed.).
164. Guidelines for design and construction of hospital and health care facilities 2006, American Institute of Architects Facility Guidelines Institute AAoAfH, US Dept of Health & Human Services, Washington, DC.
165. Goebes M.D., Baron E.J., Mathews K.L., et al. Effect of building construction on Aspergillus concentrations in a hospital. Infect Control Hosp Epidemiol 2008, 29(5):462-464.
166. Hansen D., Blahout B., Benner D., et al. Environmental sampling of particulate matter and fungal spores during demolition of a building on a hospital area. Int J Med Microbiol 2007, 297:40.
167. Nihtinen A., Anttila V.J., Richardson M., et al. The utility of intensified environmental surveillance for pathogenic moulds in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 2007, 40(5):457-460.
168. Sautour M., Sixt N., Dalle F., et al. Prospective survey of indoor fungal contamination in hospital during a period of building construction. J Hosp Infect 2007, 67(4):367-373.
169. Sixt N., Dalle F., Lafon I., et al. Reduced fungal contamination of the indoor environment with the Plasmair (TM) system (Airinspace). J Hosp Infect 2007, 65(2):156-162.
170. Grow W.B., Moreb J.S., Roque D., et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002, 29(1):15-19.
171. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7):909-917.
172. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant (HSCT) recipients. Blood 2002, 100(11):440b.
173. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992, 326(13):845-851.
174. Slavin M.A., Osborne B., Adams R., et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995, 171(6):1545-1552.
175. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10):1407-1416.
176. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335. [Erratum in: N Engl J Med. 2007;357(4):428].
177. Winston D.J., Maziarz R.T., Chandrasekar P.H., et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003, 138(9):705-713.
178. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38(2):161-189.
179. Playford E.G., Webster A.C., Sorrell T.C., et al. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006, 25(9):549-561.
180. Winston D.J., Pakrasi A., Busuttil R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131(10):729-737.
181. Benedetti E., Gruessner A.C., Troppmann C., et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996, 183(4):307-316.
182. Eggimann P., Francioli P., Bille J., et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999, 27(6):1066-1072.
183. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic HSCT recipients: results of a randomized trial. Blood 2002, 100(11):215a.
184. Rijnders B.J., Cornelissen J.J., Slobbe L., et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008, 46(9):1401-1408.